Cancer Treatment is Precisely Monitored.

The blood testing for cancer treatment follow-up with high accuracy

Get Started

DETECTING & DECODING
FOR WELL-BEING

17.9 million deaths annually from noncommunicable diseases (NCDs), with cancer being a leading cause.

Premise Biosystems’ innovative MedTech approach that paves the way for earlier interventions and improved patient outcomes by using magnetic labeling techniques in isolating rare cells in blood samples for early-stage cancer and NCDs detection.

About Us

RARMAXTM TEST

Premise Biosystems specializes in isolating rare cells from just 10 ml of blood, even when these cells are as rare as 1 in 50 million normal cells. This highly accurate process helps detect minute abnormalities, providing crucial insights into a patient’s health.

See Publications
THE NEW MEDTECH BREAKTHROUGH

We further analyze the isolated rare cells using advanced image analysis with over 30 biomarkers.

Compiled into a comprehensive, yet easy-to-understand report, offering clear explanations of the patient’s health status. The report is designed to be accessible, making it useful for both healthcare professionals and patients.

See Full RARMAX Test Report
Comprehensive, yet Easy-to-Understand
Executive Summary Report
Clear Test Results Explanation
Aspects, Markers, Reference Image, Detected Level, and Normal Range Reference

In 2030, the integration of AI and big data aims to enhance diagnostic accuracy and streamline patient care

Learn More

Dr.Suparerk Borwornpinyo

CEO and Co-Founder

Ph.D in Physiology (Biotechnolgy), North Carolina State University, Raleigh, USA

Dr. Stefan Schreier

CSO CTO and Co-Founder

Diploma degree in Bioengineering Munich University of Applied Sciences Ph.D., Dipl-Ing. Assoc. Eng Mahidol University